

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	Attorney Docket No.: SOEI0009
)	
Jun KASHIMURA et al)	Confirmation No.: 2759
)	
Serial No.: 10/715,125)	Group Art Unit: 1611
)	
Filed: November 18, 2003)	Examiner: Kevin S. Orwig
)	
For: AGENT FOR SUPPRESSING)	Date: February 18, 2010
GLUCOSE LEVEL INCREASE,)	
AGENT FOR SUPPRESSING BODY)	
FAT ACCUMULATION AND FOOD)	
COMPOUND)	

INFORMATION DISCLOSURE STATEMENT

MAIL STOP: RCE

United States Patent and Trademark Office
Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, this
Information Disclosure Statement in connection with the above-identified application is being
filed in accordance with 37 C.F.R. §1.97(b):

- ☐ within three months of the filing date of this application (not a C.P.A.);
- ☐ within three months of the date of entry of the National Stage;
- ☐ before the mailing date of a first Office Action on the merits; or
- ☒ before the mailing of a first Office Action on the merits of, after the filing of a Request for Continued Examination (RCE) under §1.114.

A copy of each non-U.S. document identified on the attached Form PTO/SB/08A is

attached, however, in accordance with Official Gazette Notice dated August 5, 2003, copies of the U.S. patents and patent application publications are not attached.

United States Patent Document 1 relates to pyridoxine derivatives, and use in therapeutics. Document 2 relates to indolizine derivatives and uses in therapeutics. Non-Patent Literature Document 1 is an excerpt from the dictionary. Documents 2-4 are cited as Exhibits F-H and are discussed in Amendment (E) filed concurrently herewith. Document 5 was previously cited in an Information Disclosure Statement and it is noted that the Examiner has agreed to consider the reference. Accordingly, no further comment with regard to the disclosures of these documents is believed to be required.

It is respectfully requested that the attached documents be considered and officially cited, and that the Examiner initial a copy of Form PTO/SB/08A and, and return it to the undersigned to indicate that the documents have been considered.

It is believed that the present Information Disclosure Statement complies with the requirements of 37 C.F.R. §§ 1.97-8, but should the filing of this paper necessitate a fee, the Director is hereby authorized to charge the necessary fee to Deposit Account No. 50-1281.

Respectfully submitted,

GRIFFIN & SZIPL, PC



Joerg-Uwe Szipl
Registration No. 31,799

GRIFFIN & SZIPL, PC
Suite PH-1
2300 Ninth Street, South
Arlington, VA 22204
Telephone: (703) 979-5700
Facsimile: (703) 979-7429
E-mail: gands@szipl.com
Customer No.: 24203